Inactive Instrument

ISIS Pharmaceuticals, Inc. Stock price Nasdaq

Equities

US4643301090

Biotechnology & Medical Research

Sales 2024 * 635M Sales 2025 * 764M Capitalization 6.13B
Net income 2024 * -583M Net income 2025 * -523M EV / Sales 2024 * 9.29 x
Net cash position 2024 * 226M Net Debt 2025 * 170M EV / Sales 2025 * 8.24 x
P/E ratio 2024 *
-10.4 x
P/E ratio 2025 *
-11.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.69%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder 58 12-06-30
Founder 62 89-01-09
Director of Finance/CFO 62 00-04-30
Members of the board TitleAgeSince
Chairman 72 14-02-02
Founder 62 89-01-09
Director/Board Member 70 19-06-09
More insiders
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on cardiovascular and neurology franchises. The Company's products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The Company has over seven medicines in Phase III studies for nine indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)), Tofersen (SOD1) and Bepirovirsen. Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, Fesomersen, ION904 and IONIS-AGT-LRx.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock Ionis Pharmaceuticals, Inc.
  4. Stock ISIS Pharmaceuticals, Inc. - Nasdaq